Company / Operating Cash Flow
Lineage Cell Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$18.9M
FY2025
5-year range
-$28.6M / -$18.9M
FY2021-FY2025
Trend
+18.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$45M in FY2017 to -$19M in FY2025.
Based on SEC 10-K filings.
-$19M in FY2025.
Improved from -$29M to -$19M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 18.1% year-over-year.
- Lowest operating cash flow in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$18.9M | +18.1% |
| FY2024 | -$23.1M | +19.2% |
| FY2023 | -$28.6M | -21.2% |
| FY2022 | -$23.6M | -19.3% |
| FY2021 | -$19.8M | +38.2% |
| FY2020 | -$31.9M | -3.4% |
| FY2019 | -$30.9M | -1.2% |
| FY2018 | -$30.5M | +31.5% |
| FY2017 | -$44.5M | -14.6% |
| FY2016 | -$38.9M | -31.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026